DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Harvard Medical School
  3. HMS Theses and Dissertations
  4. PROTEOMICS IN HEART FAILURE: RISK PREDICTION AND BIOMARKER DISCOVERY

PROTEOMICS IN HEART FAILURE: RISK PREDICTION AND BIOMARKER DISCOVERY

Open/View files
MMSCI Thesis_Dongchu Xu Final.pdf (3.93 MB)
Date
May 11, 2023
Author(s)
Xu, Dongchu
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Xu, Dongchu. 2023. PROTEOMICS IN HEART FAILURE: RISK PREDICTION AND BIOMARKER DISCOVERY. Master's thesis, Harvard Medical School.
Abstract
Heart failure remains an important clinical question despite significant advances in treatment. 1 Healthcare providers can intervene early and personalize treatment plans by predicting a patient's risk of developing heart failure or worsening symptoms. 2 Identifying new biomarkers can help guide drug development and improve the effectiveness of treatment options for heart failure patients. 3 Previous studies have revealed that machine learning (ML) -based models that consider proteomics as predictors can make more precise time-to-event predictions than traditional regression models and facilitate biomarker identification. 4,5 In our first manuscript, we investigated whether machine learning will improve risk prediction of cardiovascular death (CVD) and heart failure hospitalization (HFH) using proteomic predictors in heart failure with reduced ejection fraction (HFrEF) patients and generalize to heart failure with preserved ejection fraction (HFpEF). We then worked towards discover important proteins and pathways involved in the high performing models. In our second manuscript, we aimed to determine if a proteomic risk score derived in HFpEF patients is superior to a previous proteomic score derived in HFrEF, as well as clinical risk factors, NT-proBNP, or high-sensitivity cardiac troponin, and identify serum proteins associated with the risk of HFH and CVD in patients with HFpEF in the proteomic risk predictive model. We then analyzed the most influential prognostic proteins in HFpEF for clinical outcome prediction.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37375137
Subjects

Heart Failure

Machine Learning

Proteomics

Medicine

Health sciences

Collection
HMS Theses and Dissertations
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.